SYN-TECH Business Summary

Syn-Tech Chem. & Pharm. Co., Ltd. (1777.TWO) operates as a premier manufacturer of Active Pharmaceutical Ingredients (APIs) and fine chemicals, generating revenue through the synthesis and global distribution of high-purity intermediates. The company’s primary business segments are categorized by therapeutic application, including muscle relaxants, central nervous system (CNS) agents, cardiovascular drugs, and respiratory system treatments. Utilizing a B2B transaction-based model, Syn-Tech leverages its US FDA and PIC/S GMP-certified facilities to supply pharmaceutical manufacturers across Japan, Europe, and the United States. In the competitive landscape, Syn-Tech competes directly with domestic peers such as ScinoPharm Taiwan, Formosa Laboratories, and Everlight Chemical. It maintains a distinct market position by specializing in high-barrier synthetic processes and maintaining a strong export profile, with international sales consistently representing the majority of its annual turnover. The leadership team is anchored by Chairman Chen-Ming Hsiao and CEO Chun-Chen Hung, both of whom possess extensive experience in pharmaceutical manufacturing and strategic management within the Taiwanese biotech sector. Founded in 1982, the company has maintained a stable executive core that emphasizes R&D excellence and stringent regulatory compliance. Syn-Tech is a key subsidiary of the Standard Chem & Pharm (1720.TW) group, which serves as its primary institutional investor and strategic partner, providing significant vertical integration benefits and capital stability. The board of directors is composed of industry veterans with deep pedigrees in chemical engineering and global pharmaceutical regulations, ensuring the company remains a preferred partner for multinational drug brands seeking reliable API sourcing.